Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD.

El-Hayek JM, Rogers TE, Brown GR.

J Leukoc Biol. 2005 Oct;78(4):1001-7. Epub 2005 Aug 4.

PMID:
16081594
2.

CCR2 is required for CD8-induced graft-versus-host disease.

Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MR.

Blood. 2005 Nov 1;106(9):3322-30. Epub 2005 Jul 21.

3.

Signalling pathways of the TNF superfamily: a double-edged sword.

Aggarwal BB.

Nat Rev Immunol. 2003 Sep;3(9):745-56. Review.

PMID:
12949498
4.

Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.

Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J.

Biol Blood Marrow Transplant. 2003 May;9(5):292-303.

5.

Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.

Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MR.

Blood. 2003 Mar 15;101(6):2440-5. Epub 2002 Nov 7.

6.

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Körner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD.

Immunity. 2001 Oct;15(4):533-43.

7.
8.
9.

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL.

J Clin Invest. 1999 Aug;104(4):459-67.

10.

A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation.

Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K.

Bone Marrow Transplant. 1999 Jun;23(12):1283-9.

12.

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL.

J Clin Invest. 1998 Nov 15;102(10):1882-91.

13.

Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.

Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K.

Blood. 1998 Jun 1;91(11):4051-5.

14.

TNF receptor p55 controls early acute graft-versus-host disease.

Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K, Mak TW, Ohashi PS.

J Immunol. 1997 Jun 1;158(11):5185-90.

PMID:
9164935
15.

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.

Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD, et al.

Nature. 1997 Feb 20;385(6618):733-6. Erratum in: Nature 1997 Apr 17;386(6626):738.

PMID:
9034191
16.

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP.

Nature. 1997 Feb 20;385(6618):729-33.

PMID:
9034190
17.
18.
19.

The pathophysiology of tumor necrosis factors.

Vassalli P.

Annu Rev Immunol. 1992;10:411-52. Review. No abstract available.

PMID:
1590993

Supplemental Content

Support Center